A sad, but not surprising day for the stem cell field as the biotech StemCells, Inc. announced that it is winding down its operations after terminating its spinal cord injury trial called the Pathway Study. The data generated so far did not justify continuing the trial. StemCells, Inc. (stock symbol STEM) has struggled financially for quite some time. In February of this year I asked if the company could cheat death given how bad things were looking and what I was hearing through the …Read More
Michael Zerbe spoke at our CRISPR ethics symposium here at UC Davis this past week and made some interesting points. For more on his talk and the panel he was part of, see this post. His most provocative argument was for a warning label on CRISPR papers (see above).
Here is another of my blog posts from yesterday’s CRISPR ethics, science, and policy symposium held here at UC Davis. You can read the others here, here, and here. Note as with the other posts, since I was taking notes as listening and on the fly, this post is a stream of consciousness on what the speakers said so it is rough and there are some fragments. The next panel at the UC Davis CRISPR meeting included these speakers: Michael J. Zerbe, PhD, York College …Read More
The second session at our CRISPR meeting was really powerful. As with other posts from the UC Davis CRISPR meeting, since I was taking notes on the fly during this session, this post is a stream of bits from the different talks, often trying to capture the essence of key questions or ideas as the speakers talked so forgive the format. Overall from this session, the potential future somatic-gene therapy kind of use of CRISPR for catastrophic, fatal diseases such as Huntington’s Disease is something …Read More